Sarepta Therapeutics (SRPT) options active amid large share price sell off
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Sarepta Therapeutics (SRPT) options active amid large share price sell off
July 21, 2025 6:55 AM EDT
TD Cowen analyst Ritu Baral reiterated a Hold rating and $28.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)
The analyst comments "Lack of proactive disclosure in recent rh74 GTx-related death undermines credibility with investors. Last week, at the start of the International LGMD Conference (Orlando), unsubstantiated media reports disclosed a 51 yr old pt in the Ph1/2 trial of rh74-based GTx SRP-9004 (for LGMD Type 2D) died 11 wks post-Tx... More
July 21, 2025 6:03 AM EDT
BofA Securities analyst Tazeen Ahmad reiterated a Neutral rating and $20.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "On Friday night, Sarepta (SRPT) reported that the company received an informal request from the Food and Drug Administration (FDA) to voluntarily halt all shipments of Elevidys. The company announced they plan... More
